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Cost-Effectiveness of Magnetic Resonance Angiography
Versus Intra-arterial Digital Subtraction Angiography to
Follow-Up Patients With Coiled Intracranial Aneurysms
Joanna D. Schaafsma, MD; Hendrik Koffijberg, PhD; Erik Buskens, MD, PhD;
Birgitta K. Velthuis, MD, PhD; Yolanda van der Graaf, MD, PhD; Gabrie¨l J.E. Rinkel, MD
Background and Purpose—To follow up patients with coiled intracranial aneurysms, magnetic resonance angiography
(MRA) is a promising noninvasive alternative to current standard intra-arterial digital subtraction angiography
(IA-DSA). MRA test results do not always concord with those of IA-DSA, and the impact of discrepancies on health
benefits and costs is unknown. We evaluated the cost-effectiveness of follow-up with MRA vs IA-DSA to assess
whether in this setting MRA may replace IA-DSA.
Methods—We studied aneurysm occlusion on MRA in addition to follow-up IA-DSA in 310 patients with 341 coiled
intracranial aneurysms. The observed sensitivity (82%) and specificity (89%) of MRA for detection of reopening with
IA-DSA as a reference were used as input for a Markov decision-analytic model. Other determinants were derived from
the literature. We compared life expectancy, quality-adjusted life-years (QALY), costs, and expected number of events
for the two strategies.
Results—Follow-up with MRA yielded similar life expectancy (MRA, 26.66 years; IA-DSA, 26.63 years; difference, 0.03
years; 95% CI, 0.17–0.23) and QALY (MRA, 10.96; IA-DSA, 10.95; difference, 0.01 QALY; 95% CI, 0.05–0.08)
at lower costs (MRA, $7003; IA-DSA, $8241 per patient; difference, $1238; 95% CI, 2617-36). The expected
number of events was comparable except for complications from IA-DSA.
Conclusion—MRA provided equivalent health benefits as IA-DSA and was cost-saving. MRA dominates and should
replace routine IA-DSA to follow-up patients with coiled aneurysms. (Stroke. 2010;41:1736-1742.)
Key Words: cost-benefit analysis  digital subtraction angiography  intracranial aneurysm
 magnetic resonance angiography
Follow-up after occlusion of intracranial aneurysms withcoils is required because reopening and subsequent rup-
ture may occur.1–3 Intra-arterial digital subtraction angiogra-
phy (IA-DSA) is the standard modality to detect reopening
after coiling but is invasive and irradiating.4 Furthermore, the
procedure may cause patient discomfort and requires substan-
tial capacity of the angiography suite and inpatient clinic.
Magnetic resonance angiography (MRA) is an alternative
technique that is noninvasive, nonirradiating, and can be
performed in an outpatient setting.
To investigate whether MRA can replace IA-DSA for
follow-up of coiled patients, complete diagnostic evalua-
tion of MRA is required. This should include assessment
of its test characteristics, effect on clinical outcome, and
cost-effectiveness.5
Although test characteristics have been reported, we could
not find studies on effects on clinical outcome and cost-
effectiveness in this clinical setting. In a large prospective
series of patients, we have recently compared MRA and
IA-DSA to assess reopening of coiled aneurysms.6 This
enabled us to use the observed test characteristics of MRA
with IA-DSA as a reference to assess the expected changes in
health benefits and costs incurred using MRA or IA-DSA.
Materials and Methods
Using a cross-sectional design, we previously assessed the accuracy
for detection of reopened aneurysms in MRA with IA-DSA as a
reference in 310 coiled patients (mean age, 5112; 71% women).6
Unenhanced (time-of-flight) and contrast-enhanced MRA were per-
formed in each patient in addition to routine IA-DSA. Two observers
classified, independently from each other, the level of occlusion as
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adequate or reopening on IA-DSA and on MRA. They were blinded
for the parallel imaging modality. Sensitivity of MRA for detection
of reopened aneurysms was 82% (95% CI, 72%–89%) and speci-
ficity was 89% (95% CI, 85%–93%). Contrast-enhanced MRA did
not provide additional information to unenhanced MRA. The mean
residual lumen of undetected reopened aneurysms on MRA was
3 mm vs 6 mm for detected reopened aneurysms. Retreatment was
performed when the residual lumen appeared large enough for
additional coiling, which was the case in 44 of 76 patients (58%;
95% CI, 47%–68%) with reopened aneurysms on IA-DSA.
Evaluation of Health Benefits and Costs:
A Markov Model
We developed a Markov decision-analytic model (TreeAge Soft-
ware) to assess differences in health benefits and costs for follow-up
with MRA vs follow-up with IA-DSA.7 A Markov model is based on
probabilities of transitions between health states that we predefined
as “healthy with an occluded aneurysm,” “healthy with a reopened
aneurysm,” “disabled” (severe disability requiring a nursing home),
and “death” (Figure 1). To each health state we assigned a measure
for utility that was ultimately used to estimate quality-adjusted
life-years (QALY). Various events could cause transitions between
health states, such as complications of the diagnostic procedure or
treatment, recurrent subarachnoid hemorrhage, or unrelated events.
The probabilities of occurrence of these events and their costs were
the input parameters for the model. Then, a hypothetical cohort of
patients was run through the model with 1-month time cycles. All
started in “healthy with an occluded aneurysm” and could transit to
other health states depending on occurring events. A lifetime horizon
was used. This allowed us to simulate the individual life course of a
large hypothetical cohort to assess the change in health benefits
(QALY) and costs for a follow-up strategy with MRA vs IA-DSA.
Model Scenarios
In clinical practice, coiled patients are eligible for follow-up IA-DSA
when they regain independence for daily activities after subarach-
noid hemorrhage. In analogy to clinical practice, our model structure
was as follows: fictive patients who were independent for daily
activities entered the model at 6 months after coiling for the first
follow-up procedure, which was either IA-DSA or MRA. In case of
detected aneurysm reopening, patients could be recoiled. Recoiling
was also considered for patients with a falsely assumed reopening on
MRA. The coiling procedure that requires IA-DSA would be
interrupted on detecting an aneurysm on IA-DSA that is actually
sufficiently occluded. Conversely, undetected reopened aneurysms
on MRA or untreated reopened aneurysms could cause recurrent
subarachnoid hemorrhage. A second follow-up procedure was per-
formed at 18 months after coiling. If the aneurysm was still occluded
at 18 months of follow-up, then patients were discharged. Patients
with untreated reopened aneurysms at 18 months after coiling were
screened once more at 3.5 years after coiling. If the aneurysm was
left untreated after the 3.5-year screening, then patients were
discharged from follow-up. Complications of screening and recoiling
procedures could cause disability and death (Figure 2).
Model Parameters
Age, gender, sensitivity and specificity of MRA, and probability of
recoiling obtained from our clinical cohort were used as input
parameters of the Markov model. Other input parameters on proba-
bilities of health state transitions, utilities, and costs were derived
from the literature after a systematic PubMed search. All parameters
were discussed in a multidisciplinary setting (Table 1). For patients
who died from unrelated causes, we used age- and gender-specific
mortality rates provided by the national center of statistics in the
Netherlands, adjusted for the standardized mortality ratios of patients
after subarachnoid hemorrhage.8
The risk of reopening of coiled aneurysms decreases over
time.9–14 Based on the results of studies with different time intervals
of follow-up, we developed a univariate regression function to
predict long-term reopening risks after coiling (Supplemental Figure
I, available online at http://stroke.ahajournals.org).
Direct medical costs were incorporated. Instantaneous costs were
used for IA-DSA, MRA, recoiling, recurrent subarachnoid hemor-
rhage, and death. Long-term costs were used for disabled patients
residing in a nursing home. All costs were updated to 2007 with
Dutch inflation indices and converted to US dollars (1€$1.38, June
2009; Table 1). Future costs and effects were discounted with 4%
according to current Dutch guidelines.15
Model Assumptions
We assumed that reopened aneurysms do not occlude spontaneously
because progressive occlusion is rare.10,14 We furthermore assumed
that the risk of rupture of reopened aneurysms is constant and similar
for untreatable reopened aneurysms, undetected reopened aneu-
rysms, or aneurysms that reopened after discharge from follow-up.
Model Simulation and Outcome Measures
In our baseline scenario, we evaluated the outcomes for 50-year-old
patients with parameter values as in Table 1. Simulations were
performed for 2500 hypothetical cohorts consisting of 5000 patients
each. We compared life expectancy, health benefits in QALY,
inherent costs, and the expected number of events for follow-up with
IA-DSA and for follow-up with MRA.
We repeated the analysis for 35- and 65-year-old patient sub-
groups. We also performed cost-effectiveness analyses for the 3 age
subgroups with a discount rate of 1.5% instead of 4% for costs and
effects.15 Because the aim of follow-up is to prevent recurrent
subarachnoid hemorrhage, and because insufficient data on the
rupture risk of reopened aneurysms were available, we repeated the
analysis for different rupture rates.
Sensitivity Analyses
We explored uncertainty regarding the model input parameters with
probabilistic sensitivity analysis using Monte Carlo simulation.7,16
With Monte Carlo simulation, different samples are taken from
parameter distributions for the hypothetical cohorts to assess uncer-
tainty in cost-effectiveness estimates.
We performed additional univariate sensitivity analysis for all
model parameters defined by distributions to evaluate the association
Figure 1. State transition model. Possible transitions between
health states (circles) in our Markov model. Patients may
develop reopening, remain in the same health state, or may
move to the disability and death state because of complications
of diagnostic testing, recoiling, rebleeding, or unrelated events.
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between the model parameters with associated uncertainty and
changes in costs, effects in QALY, and cost-effectiveness.16
Results
For the baseline model, life expectancy and QALY were in
the same range for follow-up with MRA and for follow-up
with IA-DSA, whereas MRA significantly reduced costs
(Tables 2 and 3, Figure 3).
MRA induced health gain while saving costs in 67% of our
samples and induced health gain while increasing costs in
1%. Conversely, MRA reduced health benefits at lower costs
in 31% of our samples and reduced health benefits at
increased costs in 1% (Figure 3).
Life expectancy was 39.42 years (95% CI, 39.03–39.80)
after IA-DSA vs 39.47 years (95% CI, 39.04–39.91) after
MRA for 35-year old patients, 26.63 years (95% CI, 26.31–
26.95) after IA-DSA vs 26.66 years (95% CI, 26.35–26.98)
after MRA for 50-year-old patients, and 15.81 years (95% CI,
15.59–16.02) after IA-DSA vs 15.82 years (95% CI, 15.59–
16.02) after MRA for 65-year-old patients.
The number of events during follow-up with IA-DSA and
MRA was not different except for case fatality and morbidity
caused by IA-DSA (Table 2). The incidence of recurrent
subarachnoid hemorrhage was not significantly higher for
MRA than for IA-DSA. The difference in the overall case
fatality and morbidity between the diagnostic strategies was 9
out of 5000 patients in favor of follow-up by MRA.
Scenario analyses for different ages, discount rates, and
rupture rates of reopened aneurysms yielded similar results as
for the baseline model. MRA remained cost-saving with a
similar change in QALY compared to IA-DSA (Table 3). For
50-year-old patients MRA gained slightly more QALY in
68%, for 35-year-old patients in 72%, and for 65-year-old
patients in 64% of the sampled cohorts. The probability of
health gain by MRA increases with decreasing age. The
cost-saving provided by MRA was similar in all our scenarios
and was apparently not largely influenced by patient age, the
rupture risk, or the discount rate used in the model.
Sensitivity analysis demonstrated that the distribution of
input parameters did not significantly influence costs or
QALY. We did not find an association between values of
single-model parameters and cost-effectiveness estimates.
Discussion
Follow-up after coiling of intracranial aneurysms by MRA
results in similar health benefits but lower costs than
follow-up by IA-DSA. The expected number of events was
similar for both strategies, except for morbidity and case
fatality caused by IA-DSA. Nevertheless, these complications
did not have a major impact on cost-effectiveness because the
total number of expected complications of IA-DSA remained
small, particularly in comparison to patients with atheroscle-
rosis.4 The complication risk of MRA with contrast agent is
extremely small.17,18 We incorporated this small risk into the
Figure 2. This simplified part of the
decision tree used in the Markov model
illustrates follow-up with MRA. TP, true-
positive; FN, false-negative; TN, true-
negative; FP, false-positive test result.
The branch for IA-DSA is not displayed.
1738 Stroke August 2010
 at Rijksuniversiteit Groningen on October 26, 2010 stroke.ahajournals.orgDownloaded from 
model, even though in our clinical study and other studies
contrast-enhanced MRA did not provide significant addi-
tional information for unenhanced MRA.19,20 So, the admin-
istration of contrast agent is often unnecessary, which de-
creases the morbidity risk of MRA even further. Moreover,
those reopened aneurysms on IA-DSA that were not identi-
fied on MRA did not significantly increase the expected
incidence of subarachnoid hemorrhage for patients
followed-up with MRA. As a result of less than optimal
quality of life after subarachnoid hemorrhage, life expectancy
considerably surpasses the number of QALY, regardless of
the strategy.
MRA appeared to be cost-saving. Because the number of
events does not largely differ between the two strategies, the
difference in costs is likely to be caused by the lower costs of
MRA compared to the IA-DSA procedure. When cost reduc-
Table 1. Model Input Parameters
Model Parameter Value 95% CI/Range* Distribution Source
Probabilities
Sensitivity MRA 0.82 0.72–0.89 Beta CS
Specificity MRA 0.89 0.85–0.93 Beta CS
P (case fatality of IA-DSA) 0.0006 0.0003–0.0010 Beta 4
P (morbidity of IA-DSA) 0.0010 0.0006–0.0015 Beta 4
P (case fatality of MRA) 0.0000000 . . . . . . 17, 18
P (morbidity of MRA) 0.0000053 0.0000026–0.0000088 Beta 17, 18
P (case fatality recoiling) 0.0056 0.0018–0.0120 Beta 24–27
P (morbidity recoiling) 0.011 0.004–0.021 Beta 26, 27
P (case fatality rebleeding) 28
30–39 y 0.182 0.162–0.204 Beta
40–49 y 0.225 0.211–0.240 Beta
50–59 y 0.249 0.236–0.262 Beta
60–69 y 0.317 0.310–0.324 Beta
70–79 y 0.455 0.438–0.472 Beta
80 y 0.576 0.553–0.598 Beta
P (morbidity rebleeding) 0.09 0.08–0.11 Beta 29, 30
P (case fatality disabled patients) per year 0.24 0.10–0.36 Uniform 28, 31
P (reopening) up to 6 mo after coiling† 0.119 0.097–0.144 Beta 10, 11, 13
P (reopening) 6–18 mo after coiling† 0.055 0.019–0.110 Beta 9, 11, 14
P (reopening) 18 mo–6 y after coiling† 0.036 0.010–0.078 Beta 12
P (recoiling reopened aneurysm) 0.58 0.47–0.68 Beta CS
P (rupture risk reopening) per year 0.017 0.014–0.020 Uniform 10, 12, 22, 23, 32
Costs ($)
Costs IA-DSA $838 . . . . . . 33
Costs MRA $371 . . . . . . 33
Costs of rebleeding including recoiling $36 920 . . . . . . 34, 35
Costs of elective recoiling $12 646 . . . . . . 33
Costs nursing home per year $107 711 . . . . . . 15
Costs of patient death $3585 . . . . . . 36
Utilities
Well after subarachnoid hemorrhage 0.72 0.65–0.80 Triangular 37
Disabled 0.25 0.21–0.30 Triangular 37
Dead 0 . . . . . .
Discounting
Cost discount per year 4% . . . . . . . . .
Effect discount per year 4% . . . . . . . . .
CS indicates data obtained from our clinical study; IA-DSA, intra-arterial digital subtraction angiography; MRA, magnetic resonance
imaging.
*95% CI for beta distribution; range for uniform/triangular distribution.
†A mathematical function based on these results was used (provided online). All rates obtained were converted to probabilities per
month.
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tion is not taken into consideration, there is still a substantial
chance that MRA is the preferred strategy with a small gain
in QALY, especially for younger patients.
We could not find other studies on cost-effectiveness of
MRA vs IA-DSA after coiling. Using a Markov model, we
integrated the best available evidence for computation of the
expected long-term outcomes. A diagnostic, randomized,
clinical trial, although theoretically more accurate, would be
infeasible because a large number of participants and long
follow-up is required to ascertain the incidence of rupture of
undetected or untreated reopened aneurysms.5
We intended to construct a detailed Markov model that
appropriately reflects clinical practice, although we faced
some limitations. First, IA-DSA is not a perfect reference
standard for follow-up of coiled aneurysms. For example, the
2-dimensional images restrict visualization of residual flow in
case of superimposition of coils or surrounding arteries.21
Consequently, discrepant results on MRA had to be labeled as
“false-positive” or “false-negative,” whereas MRA may pro-
vide the more realistic visualization. Thus, the model repre-
sented the least favorable scenario for MRA and therefore
may underestimate its diagnostic performance. MRA still
appeared dominant, thus strengthening the conclusion that
MRA may replace IA-DSA.
Second, input parameters originated from our clinical study
and from the literature. Because coiling has been available
since 1992, only limited data on reopening and subsequent
rupture rates more than 5 to 10 years after coiling are
available.1,2,10,22,23 Reopening rates could only be estimated
from a few studies with a systematic long-term follow-up at
fixed time intervals.3,9–14
Third, for the model, we assumed a similar rupture rate for
aneurysms that reopened after follow-up for untreatable and
for undetected reopened aneurysms, whereas the actual rup-
ture risks may differ in each situation. Undetected reopened
aneurysms in our clinical study were smaller and therefore
probably had a lower rupture rate than larger reopened
aneurysms that are left untreated. By assuming a similar
rupture rate, we overestimated the health loss from undetec-
ted aneurysms when using MRA and therefore underesti-
mated the health benefits provided by MRA. Repeated
analyses for different rupture rates resulted in marginal and
similar changes in QALY and costs. So, the uncertainty
around the exact rupture rate did not influence the cost-
effectiveness of MRA compared to IA-DSA. We furthermore
assumed that reopened aneurysms never occlude spontane-
ously. In case of spontaneous occlusion, the potential hazard
of a nonidentified reopened aneurysm on MRA would be
smaller. So, again, we applied the least favorable scenario for
MRA to avoid positive bias.
Table 2. Costs and Effects for Follow-Up With IA-DSA vs MRA
IA-DSA MRA Difference 95% CI
Life expectancy
per patient, y
26.63 26.66 0.03 0.17–0.23
QALY per patient 10.95 10.96 0.01 0.05–0.08
Total case fatality
strategy, n
125 120 5 24–13
Total morbidity
strategy, n
38 34 4 16–11
Case fatality
recoiling, n
5 5 0 3–2
Morbidity
recoiling, n
9 9 0 4–3
Case fatality
test, n
7 0 7 14–2*
Morbidity test, n 11 0 11 20–4*
Reopened
aneurysms, n
1359 1360 1 28–31
Recoiling
procedures, n
728 718 10 29–7
Rebleedings, n 191 196 5 12–22
Costs per patient $8241 $7003 $1238 2617–36*
The cost-effectiveness estimates based on simulations of 2500 cohorts of
5000 patients each.
IA-DSA, intra-arterial digital subtraction angiography; MRA, magnetic reso-
nance imaging; QALY, quality-adjusted life-year.
*Statistically significant.
Table 3. Scenario Analyses
Age, y DR, % Rupture Risk*
Costs, $ QALY
Costs 95% CI QALY 95% CIIA-DSA MRA IA-DSA MRA
35 4 0.017 8240 7001 13.40 13.42 1238 (2663–75) 0.02 (0.04–0.08)
50 4 0.017 8241 7003 10.95 10.96 1238 (2617–36) 0.01 (0.05–0.08)
65 4 0.017 8290 7015 7.95 7.96 1275 (2523–199) 0.01 (0.04–0.06)
35 1.5 0.017 11 322 10 068 20.76 20.79 1254 (2899–290) 0.03 (0.09–0.13)
50 1.5 0.017 10 438 9153 15.29 15.31 1284 (2979–72) 0.02 (0.08–0.12)
65 1.5 0.017 9743 8403 9.90 9.91 1340 (2894–50) 0.01 (0.06–0.09)
50 4 0.034 9284 8056 10.90 10.91 1227 (2588–6) 0.01 (0.05–0.07)
50 4 0.014 7897 6653 10.96 10.98 1244 (2295–108) 0.02 (0.05–0.09)
50 4 0.009 7546 6291 10.98 10.99 1255 (2492–61) 0.01 (0.05–0.07)
50 4 0.005 7135 5871 11.00 11.01 1264 (2677–122) 0.01 (0.05–0.08)
Each analysis comprised 1000 simulations for 5000 patients.
DR, discount rate; IA-DSA, intra-arterial digital subtraction angiography; MRA, magnetic resonance imaging; QALY, quality-adjusted life-year.
*Rupture risk of reopened aneurysm per year.
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Fourth, we did not evaluate the influence of uncertainty in
costs on the cost-effectiveness of MRA vs IA-DSA because
insufficient evidence was available to define their distribu-
tion. Finally, because information on actual dependencies
between model parameters could not be obtained, all param-
eters were, by necessity, assumed to be independent in our
probabilistic sensitivity analysis. This assumption may not
hold for all parameters, eg, for sensitivity and specificity.
Nevertheless, because the sensitivity analyses showed overall
robust outcomes, we feel that our general conclusion remains
justified.
MRA is a safe technique that can be performed in an
outpatient setting. Our results show that the consequences of
misdiagnosis by MRA outweigh the complications caused by
IA-DSA and that MRA reduces costs. We therefore recom-
mend using MRA instead of IA-DSA to follow-up coiled
patients. The exact timing of reopening and subsequent
rupture after coiling is unclear. Additional studies on timing
of follow-up MRA are warranted to assess the short-term and
long-term evolution of coiled aneurysms.
Conclusion
Cost-effectiveness analysis by Markov modeling shows that
potential consequences of misdiagnosis by MRA will be
offset by the direct risk of complications associated with
IA-DSA, and MRA will reduce costs considerably. Patients
therefore should be followed-up by MRA instead of IA-DSA
to detect reopening after coiling of intracranial aneurysms.
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